|Study Description:||This study is divided into study groups, as described below. The goal of |
Groups 1A and 2A of this clinical research study is to find the highest
tolerable dose of the combination of ARRY-520 and carfilzomib that can be given
to patients with multiple myeloma or plasma cell leukemia.
The goal of Groups 1B and 2B of this study is to learn if the combination of
carfilzomib and ARRY-520 can help to control multiple myeloma or plasma cell
leukemia. Researchers would also like to learn if ARRY-520 can help
carfilzomib to work in patients who have built up a resistance to carfilzomib
or carfilzomib alone has not helped to control the disease.
The safety of the study drugs will be studied in all groups.